Most linked-to pages

Showing below up to 50 results in range #51 to #100.

51. Keppra (Levetiracetam)‏‎ (3 links)
52. Limonene‏‎ (3 links)
53. Melatonin‏‎ (3 links)
54. Metabolic therapy with Sodium R lipoate plus hydroxycitrate‏‎ (3 links)
55. Not applicable; studies focusing on PFS-6 as a primary endpoint‏‎ (3 links)
56. Not reached at a median follow-up of 5.8 months‏‎ (3 links)
57. Not specified in the provided text‏‎ (3 links)
58. PFS-6 value was 53% in a restricted patient population with overexpression of PDGFR‏‎ (3 links)
59. PSK‏‎ (3 links)
60. Parthenolide‏‎ (3 links)
61. Proton Beam Therapy (PBT)‏‎ (3 links)
62. Proton Radiation Therapy‏‎ (3 links)
63. Resveratrol‏‎ (3 links)
64. Sativex‏‎ (3 links)
65. Sativex (Nabiximols)‏‎ (3 links)
66. Sulforaphane‏‎ (3 links)
67. This vaccine represents a promising strategy by targeting CMV antigens present in GBM cells, potentially extending survival significantly beyond standard treatments. Initial results suggest substantial benefits for certain patient groups.‏‎ (3 links)
68. VT-122‏‎ (3 links)
69. VT-122 (Propranolol and Etodolac combination)‏‎ (3 links)
70. Vitamin D‏‎ (3 links)
71. Category:Repurposed Drugs‏‎ (3 links)
72. MediaWiki:Smw import foaf‏‎ (3 links)
73. Standard Treatments‏‎ (3 links)
74. Data not specified‏‎ (3 links)
75. Phase II‏‎ (3 links)
76. Complementary and Self-Directed Therapies‏‎ (3 links)
77. Research It Yourself‏‎ (3 links)
78. 14-16 months with standard treatment.‏‎ (2 links)
79. 16 months (control group in EF-14 Trial)‏‎ (2 links)
80. 17% in the study of patients with tumors recurring after radiation; 38% in a study using PCV for tumors recurrent after radiation (and for some after prior chemotherapy); 13% in a study with PCV after Temodar failure‏‎ (2 links)
81. 20.9 months (Optune plus temozolomide, final EF-14 analysis)‏‎ (2 links)
82. 5.6 months reported in recent studies using fractionated sessions with Gamma Knife ICON.‏‎ (2 links)
83. 8.0 months mOS observed in phase 2 trial for patients receiving treatment dose of 30 mg/m2/day‏‎ (2 links)
84. ABT-414‏‎ (2 links)
85. Agenus Prophage (Heat-Shock Protein Peptide Complex-96) Vaccine‏‎ (2 links)
86. Angiotensin-II Receptor Blockers (ARB)‏‎ (2 links)
87. Anlotinib‏‎ (2 links)
88. Anti-CMV Dendritic Cell Vaccine‏‎ (2 links)
89. Based on available data, potentially highly useful in specific dosing schedules‏‎ (2 links)
90. Chronotherapy‏‎ (2 links)
91. Chronotherapy with Temozolomide (TMZ)‏‎ (2 links)
92. Comparable to standard treatment, specifics depend on individual patient factors.‏‎ (2 links)
93. Data on progression-free survival specifically for SL-701 is under investigation; significant antitumor activity has been noted.‏‎ (2 links)
94. Data varies; traditional radiation therapies offer median OS of around 16-21 months for glioblastoma‏‎ (2 links)
95. Dendritic Cell Vaccine (DCVax-L)‏‎ (2 links)
96. Disulfiram‏‎ (2 links)
97. Early studies indicate variable results; ongoing trials, including combinations with PARP inhibitors, aim to determine efficacy‏‎ (2 links)
98. Early trials show median survival times from 56 weeks for recurrent GBM to up to 24.9 months in certain cohorts‏‎ (2 links)
99. Enhancements in progression-free survival noted in combination therapies, ranging from improvement in median progression-free survival times to higher 6-month survival rates‏‎ (2 links)
100. Gamma Knife Radiosurgery‏‎ (2 links)